Brief: Jazz pharmaceuticals and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan
30/03/2017 07:00
March 30 (Reuters) - Jazz pharmaceuticals JAZZ.O :
* Jazz Pharmaceuticals Plc - co and Nippon Shinyaku enter into license agreements for
development and commercialization of Defitelio and Vyxeos in Japan
* Jazz Pharmaceuticals - will manufacture, supply Defitelio and Vyxeos to Nippon Shinyaku;
will receive revenue based on percent of product sales in Japan
Source text for Eikon: ID:nPn9PzjLBa
Further company coverage: 4516.T
(Bengaluru Newsroom)
((+1 646 223 8780;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)